Common Contracts
22 similar Placement Agency Agreement contracts by Nano Dimension Ltd., Biovie Inc., BriaCell Therapeutics Corp., others
ContractPlacement Agency Agreement • October 24th, 2024 • Biovie Inc. • Pharmaceutical preparations • New York
CERTAIN PERSONALLY IDENTIFIABLE INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.
PLACEMENT AGENCY AGREEMENT between BRIACELL THERAPEUTICS CORP. and THINKEQUITY LLC BRIACELL THERAPEUTICS CORP. PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • October 2nd, 2024 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • New York
This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC (“ThinkEquity” or the “Placement Agent”) shall be engaged by BriaCell Therapeutics Corp., a corporation formed under the laws of the Province of British Columbia (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of BriaCell Therapeutics Corp., the “Company”), to act as the exclusive placement agent in connection with the offering (hereinafter referred to as the “Offering”) of up to 5,128,500 units (the “Units”) of the Company, consisting of 5,128,500 Class A Units (as defined below) and 0 Class B Units (as defined below), each consisting of either: (A) one common share, with no par value per common share (each, a “Common Share”) and one warrant (each, a “Warrant”) to purchase one Common Share at an exercise price of $0.85 for a peri
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • September 24th, 2024 • Biovie Inc. • Pharmaceutical preparations • New York
Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity LLC (“ThinkEquity” or the “Placement Agent”) shall be engaged by BioVie Inc., a Nevada corporation (the “Company”), to act as the exclusive Placement Agent in connection with the offering (hereinafter referred to as the “Offering”) of up to 1,960,800 shares (the “Shares”) of the Company’s class A common stock, $0.0001 par value per share (the “Common Stock”), and/or pre-funded common stock purchase warrants to purchase one share of Common Stock (the “Pre-Funded Warrants”), together with common stock purchase warrants to purchase up to 1,960,800 shares of Common Stock (the “Warrants,” the shares of Common Stock underlying the Pre-Funded Warrants and Warrants, the “Warrant Shares”, and the Shares, the Pre-Funded Warrants, Warrants and the Warrant Shares, the “Securities”) directly to various investors (each, an “Investor” and, collectively, the “Investors”). The purchase price to t
CERTAIN PERSONALLY IDENTIFIABLE INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • March 4th, 2024 • Biovie Inc. • Pharmaceutical preparations • New York
Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity LLC (“ThinkEquity” or the “Placement Agent”) shall be engaged by BioVie Inc., a Nevada corporation (the “Company”), to act as the exclusive Placement Agent in connection with the offering (hereinafter referred to as the “Offering”) of up to 21,000,000 shares (the “Shares”) of the Company’s class A common stock, $0.0001 par value per share (the “Common Stock”), and/or pre-funded common stock purchase warrants to purchase one share of Common Stock (the “Pre-Funded Warrants”), together with common stock purchase warrants to purchase up to 10,500,000 shares of Common Stock (the “Warrants,” the shares of Common Stock underlying the Pre-Funded Warrants and Warrants, the “Warrant Shares”, and the Shares, the Pre-Funded Warrants, Warrants and the Warrant Shares, the “Securities”) directly to various investors (each, an “Investor” and, collectively, the “Investors”). The purchase price to
PLACEMENT AGENCY AGREEMENT January 13, 2021Placement Agency Agreement • January 15th, 2021 • Nano Dimension Ltd. • Printed circuit boards • New York
Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division of Fordham Financial Management, Inc., (“ThinkEquity” or the “Placement Agent”) shall be engaged by Nano Dimension Ltd., a company organized under the laws of the State of Israel (the “Company”), to act as the exclusive Placement Agent in connection with the registered direct offering (hereinafter referred to as the “Offering”) of American Depositary Shares (“ADS”), each ADS representing one (1) ordinary share, par value NIS 5.00 per share (the “Ordinary Shares” and, together with the ADSs, the “Public Securities”), of the Company deposited with the Depositary (as defined below), as more fully described below. Capitalized terms used but not defined in this Agreement shall have the meaning ascribed to them in the Securities Purchase Agreement to be entered into in connection with the Offering, in the form of Exhibit A (collectively, the “Securities Purchase Agreement”)
PLACEMENT AGENCY AGREEMENT December 27, 2020Placement Agency Agreement • December 28th, 2020 • Nano Dimension Ltd. • Printed circuit boards • New York
Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division of Fordham Financial Management, Inc., (“ThinkEquity” or the “Placement Agent”) shall be engaged by Nano Dimension Ltd., a company organized under the laws of the State of Israel (the “Company”), to act as the exclusive Placement Agent in connection with the registered direct offering (hereinafter referred to as the “Offering”) of American Depositary Shares (“ADS”), each ADS representing one (1) ordinary share, par value NIS 5.00 per share (the “Ordinary Shares” and, together with the ADSs, the “Public Securities”), of the Company deposited with the Depositary (as defined below), as more fully described below. Capitalized terms used but not defined in this Agreement shall have the meaning ascribed to them in the Securities Purchase Agreement to be entered into in connection with the Offering, in the form of Exhibit A (collectively, the “Securities Purchase Agreement”)
PLACEMENT AGENCY AGREEMENT December 6, 2020Placement Agency Agreement • December 7th, 2020 • Nano Dimension Ltd. • Printed circuit boards • New York
Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division of Fordham Financial Management, Inc., (“ThinkEquity” or the “Placement Agent”) shall be engaged by Nano Dimension Ltd., a company organized under the laws of the State of Israel (the “Company”), to act as the exclusive Placement Agent in connection with the registered direct offering (hereinafter referred to as the “Offering”) of American Depositary Shares (“ADS”), each ADS representing one (1) ordinary share, par value NIS 5.00 per share (the “Ordinary Shares” and, together with the ADSs, the “Public Securities”), of the Company deposited with the Depositary (as defined below), as more fully described below. Capitalized terms used but not defined in this Agreement shall have the meaning ascribed to them in the Securities Purchase Agreement to be entered into in connection with the Offering, in the form of Exhibit A (collectively, the “Securities Purchase Agreement”)
PLACEMENT AGENCY AGREEMENT November 29, 2020Placement Agency Agreement • November 30th, 2020 • Nano Dimension Ltd. • Printed circuit boards • New York
Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division of Fordham Financial Management, Inc., (“ThinkEquity” or the “Placement Agent”) shall be engaged by Nano Dimension Ltd., a company organized under the laws of the State of Israel (the “Company”), to act as the exclusive Placement Agent in connection with the registered direct offering (hereinafter referred to as the “Offering”) of American Depositary Shares (“ADS”), each ADS representing one (1) ordinary share, par value NIS 5.00 per share (the “Ordinary Shares” and, together with the ADSs, the “Public Securities”), of the Company deposited with Bank Hapoalim or Bank Leumi, as custodian for the Depositary (as defined below) in Tel Aviv of the Company, as more fully described below. Capitalized terms used but not defined in this Agreement shall have the meaning ascribed to them in the Securities Purchase Agreement to be entered into in connection with the Offering, in
PLACEMENT AGENCY AGREEMENT November 19, 2020Placement Agency Agreement • November 23rd, 2020 • Nano Dimension Ltd. • Printed circuit boards • New York
Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division of Fordham Financial Management, Inc., (“ThinkEquity” or the “Placement Agent”) shall be engaged by Nano Dimension Ltd., a company organized under the laws of the State of Israel (the “Company”), to act as the exclusive Placement Agent in connection with the registered direct offering (hereinafter referred to as the “Offering”) of American Depositary Shares (“ADS”), each ADS representing one (1) ordinary share, par value NIS 5.00 per share (the “Ordinary Shares” and, together with the ADSs, the “Public Securities”), of the Company deposited with Bank Hapoalim or Bank Leumi, as custodian for the Depositary (as defined below) in Tel Aviv of the Company, as more fully described below. Capitalized terms used but not defined in this Agreement shall have the meaning ascribed to them in the Securities Purchase Agreement to be entered into in connection with the Offering, in
PLACEMENT AGENCY AGREEMENT October 26, 2020Placement Agency Agreement • October 27th, 2020 • Nano Dimension Ltd. • Printed circuit boards • New York
Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division of Fordham Financial Management, Inc., (“ThinkEquity” or the “Placement Agent”) shall be engaged by Nano Dimension Ltd., a company organized under the laws of the State of Israel (the “Company”), to act as the exclusive Placement Agent in connection with the registered direct offering (hereinafter referred to as the “Offering”) of American Depositary Shares (“ADS”), each ADS representing one (1) ordinary share, par value NIS 5.00 per share (the “Ordinary Shares” and, together with the ADSs, the “Public Securities”), of the Company deposited with Bank Hapoalim or Bank Leumi, as custodian for the Depositary (as defined below) in Tel Aviv of the Company, as more fully described below. Capitalized terms used but not defined in this Agreement shall have the meaning ascribed to them in the Securities Purchase Agreement to be entered into in connection with the Offering, in
PLACEMENT AGENCY AGREEMENT September 30, 2020Placement Agency Agreement • October 2nd, 2020 • Nano Dimension Ltd. • Printed circuit boards • New York
Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division of Fordham Financial Management, Inc., (“ThinkEquity” or the “Placement Agent”) shall be engaged by Nano Dimension Ltd., a company organized under the laws of the State of Israel (the “Company”), to act as the exclusive Placement Agent in connection with the registered direct offering (hereinafter referred to as the “Offering”) of American Depositary Shares (“ADS”), each ADS representing one (1) ordinary share, par value NIS 5.00 per share (the “Ordinary Shares” and, together with the ADSs, the “Public Securities”), of the Company deposited with Bank Hapoalim or Bank Leumi, as custodian for the Depositary (as defined below) in Tel Aviv of the Company, as more fully described below. Capitalized terms used but not defined in this Agreement shall have the meaning ascribed to them in the Securities Purchase Agreement to be entered into in connection with the Offering, in
PLACEMENT AGENCY AGREEMENT between BRIACELL THERAPEUTICS CORP. and THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. as Placement Agent BRIACELL THERAPEUTICS CORP.Placement Agency Agreement • May 27th, 2020 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • New York
The undersigned, BriaCell Therapeutics Corp., a corporation formed under the laws of the Province of British Columbia (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of BriaCell Therapeutics Corp. (the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity, a division of Fordham Financial Management, Inc., (hereinafter referred to as “you” (including its correlatives) or the “Placement Agent”) as follows:
PLACEMENT AGENCY AGREEMENT May 20, 2020Placement Agency Agreement • May 20th, 2020 • Nano Dimension Ltd. • Printed circuit boards • New York
Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division of Fordham Financial Management, Inc., (“ThinkEquity” or the “Placement Agent”) shall be engaged by Nano Dimension Ltd., a company organized under the laws of the State of Israel (the “Company”), to act as the exclusive Placement Agent in connection with the registered direct offering (hereinafter referred to as the “Offering”) of American Depositary Shares (“ADS”), each ADS representing fifty (50) ordinary shares, par value NIS 0.1 per share (the “Ordinary Shares” and, together with the ADSs, the “Public Securities”), of the Company deposited with Bank Hapoalim or Bank Leumi, as custodian for the Depositary (as defined below) in Tel Aviv of the Company, as more fully described below. Capitalized terms used but not defined in this Agreement shall have the meaning ascribed to them in the Securities Purchase Agreement to be entered into in connection with the Offering,
PLACEMENT AGENCY AGREEMENT between BIOVIE INC. and THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. as Placement Agent BIOVIE INC.Placement Agency Agreement • March 11th, 2020 • Biovie Inc. • Pharmaceutical preparations • New York
The undersigned, BioVie Inc., a corporation formed under the laws of the State of Nevada (the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity, a division of Fordham Financial Management, Inc., (hereinafter referred to as “you” (including its correlatives) or the “Placement Agent”) as follows:
PLACEMENT AGENCY AGREEMENT June 17, 2019Placement Agency Agreement • June 17th, 2019 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division of Fordham Financial Management, Inc., (“ThinkEquity” or the “Placement Agent”) shall be engaged by Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), to act as the exclusive Placement Agent in connection with the offering (hereinafter referred to as the “Offering”) of securities of the Company, as more fully described below. Capitalized terms used but not defined in this Agreement shall have the meaning ascribed to them in the Securities Purchase Agreement (defined below).
Matinas biopharma holdings, Inc. (a Delaware corporation) 8,000 Shares of Series B Convertible Preferred Stock PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • June 19th, 2018 • Matinas BioPharma Holdings, Inc. • Pharmaceutical preparations • New York
Matinas BioPharma Holdings, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the purchasers (each, a “Purchaser” and, collectively, the “Purchasers”), pursuant to the terms and conditions of this Placement Agent Agreement (this “Agreement”) up to an aggregate of 8,000 shares (the “Shares”) of Series B Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”). The offering and sale of the Shares of Series B Preferred Stock is hereinafter referred to as the “Offering.” The Company hereby confirms its agreement with ThinkEquity, a division of Fordham Financial Management, Inc. (the “Placement Agent”) to act as Placement Agent in accordance with the terms and conditions hereof.
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • November 9th, 2015 • Ominto, Inc. • Services-business services, nec • New York
Introduction. Subject to the terms and conditions herein (this “Agreement”), Ominto, Inc., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $[__] of registered securities of the Company, including, but not limited to, shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), together with warrants to purchase Common Stock at an exercise price of $__ per share (the “Warrants” and the shares of Common Stock underlying the Warrants, the “Warrant Shares”), (the Shares, Warrants and Warrant Shares, collectively, the “Securities”) directly to various investors (each, an “Investor” and, collectively, the “Investors”) through Chardan Capital Markets, LLC, as placement agent (the “Placement Agent”). The Placement Agent may retain other brokers or dealers to act as sub-agents or selected-dealers on its behalf in connection with the Offering (as defined below) whose fees and expenses shall be borne exclusively by the Pla
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • November 18th, 2013 • Z Trim Holdings, Inc • Grain mill products • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • November 4th, 2013 • Z Trim Holdings, Inc • Grain mill products • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • July 17th, 2013 • Oxygen Biotherapeutics, Inc. • Services-commercial physical & biological research • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • June 29th, 2012 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances) • New York
3,833,108 Shares Warrants to Purchase 1,916,554 Shares DELCATH SYSTEMS, INC. Common Stock PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • September 24th, 2007 • Delcath Systems Inc • Surgical & medical instruments & apparatus • New York
Delcath Systems, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this Placement Agency Agreement (this “Agreement”) and the Subscription Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with the investors identified therein (each, an “Investor” and collectively, the “Investors”), to issue and sell up to an aggregate of 3,833,108 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”). Each Investor shall also receive a warrant, in the form of Exhibit B attached hereto, to purchase up to a number of shares of the Company’s Common Stock (the “Warrant Shares”) equal to fifty percent (50%) of the number of Shares purchased by such Investor, at an exercise price equal to $4.53 per share, exercisable beginning six months after the issuance thereof and on or prior to the fifth anniversary of the issuance thereof (the “Warrants” and together with the
